efpeglenatide vs Liraglutide (Saxenda)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
efpeglenatide
Marketed by Hanmi Pharmaceutical and partners
NCT06174779 · Phase 3 · completed
The trial randomized 448 participants to drug or placebo under double-blind conditions, with percent body-weight loss as the primary measure. Participants on the drug lost significantly more weight than those on placebo, a difference of about 8 percentage points.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
The percent change of body weight from baseline (baseline, 40 weeks); The proportion of subjects achieving body weight loss ≥ 5% from baseline (baseline, 40 weeks): Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant (met)
Result source: NCT06174779
Liraglutide (Saxenda)
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
Reported efficacy
Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)
Result source: NCT02918279
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | efpeglenatide | Liraglutide (Saxenda) |
|---|---|---|
| Body weight, % change | -9.8% vs -0.9%a−8.8 vs placeboNCT06174779 | -8.0% vs -2.6%−5.4 vs placeboNCT0127221920 other results
|
| Weight loss of 5% or more | —Not posted · NCT06174779 | 63.2% vs 27.1%+36.1 vs placeboNCT012722194 other results
|
| Weight loss of 10% or more | —Not posted · NCT06174779 | 33.1% vs 10.6%+22.5 vs placeboNCT012722193 other results
|
| Waist circumference, change (cm) | —Not posted · NCT06174779 | -6.9 vs -3.4−3.5 vs placeboNCT0127221924 other results
|
Body weight, % change
- efpeglenatide
- -9.8% vs -0.9%a−8.8 vs placeboNCT06174779
- Liraglutide (Saxenda)
- -8.0% vs -2.6%−5.4 vs placeboNCT01272219
20 other results
- -6.1% vs -0.1% NCT00781937
- -5.9% vs -2% NCT01272232
- -4.6% vs -2% NCT01272232
- -7.7% vs -6.5% NCT03374956
- -6.1% vs -1.9% NCT01272219
- 0.7% vs 0.3% NCT01272219
- 2.9% vs 0.3% NCT01272219
- -8.4% vs -3.1% NCT01272219
- -6.8% vs -3.1% NCT01272219
- -4.7% vs -2.7% NCT01272232
- -3.6% vs -2.7% NCT01272232
- -5.7% vs -1.4% NCT03480022
- -0.4% vs 3.3% NCT02527200
- 6.3% vs 3.3% NCT02527200
- 2.6% vs 3.3% NCT02527200
- -1.7% vs -1.2% NCT02527200
- -1.1% vs -1.2% NCT02527200
- -1.4% vs -1.2% NCT02527200
- -3.3% vs 0.2% NCT03158805
- -6.6% vs -1.2% NCT03038620
Weight loss of 5% or more
- efpeglenatide
- —Not posted · NCT06174779
- Liraglutide (Saxenda)
- 63.2% vs 27.1%+36.1 vs placeboNCT01272219
4 other results
- 50.5% vs 21.9% NCT00781937
- 49.9% vs 13.8% NCT01272232
- 35.6% vs 13.8% NCT01272232
- 76% vs 17% NCT03048578
Weight loss of 10% or more
- efpeglenatide
- —Not posted · NCT06174779
- Liraglutide (Saxenda)
- 33.1% vs 10.6%+22.5 vs placeboNCT01272219
3 other results
- 23.4% vs 4.3% NCT01272232
- 14.4% vs 4.3% NCT01272232
- 26.1% vs 6.3% NCT00781937
Waist circumference, change (cm)
- efpeglenatide
- —Not posted · NCT06174779
- Liraglutide (Saxenda)
- -6.9 vs -3.4−3.5 vs placeboNCT01272219
24 other results
- -8.2 vs -3.9 NCT01272219
- -5.7 vs -3.2 NCT01272232
- -4.4 vs -0.9 NCT00781937
- -6.1 vs -2.7 NCT01272232
- -4.4 vs -3.2 NCT01272232
- -4.8 vs -2.7 NCT01272232
- 100.9 vs 109.9 NCT03480022
- -3.0 vs -2.1 NCT02527200
- 0.5 vs -2.1 NCT02527200
- -1.5 vs -2.1 NCT02527200
- -2.5 vs -1.9 NCT02527200
- -0.7 vs -1.9 NCT02527200
- -1.7 vs -1.9 NCT02527200
- -7.4 vs -4.6 NCT03038620
- -9.8 vs -9.5 NCT00422058
- -7.9 vs -6 NCT00422058
- -9 vs -9.5 NCT00422058
- -5.9 vs -6 NCT00422058
- -10 vs -9.5 NCT00422058
- -10.4 vs -9.5 NCT00422058
- -4.2 vs -6 NCT00422058
- -7.2 vs -6 NCT00422058
- -8.6 vs -9.5 NCT00422058
- -5.8 vs -6 NCT00422058
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. efpeglenatide: 0 of 4 rows · Liraglutide (Saxenda): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | efpeglenatide | Liraglutide (Saxenda) |
|---|---|---|
| Dropout rate | — | 25%3.0 mga NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results27.4%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 29.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 23.4%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 22.3%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 25.6%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 10.4%3.0 mg NCT02918279 · Phase 3 22.7%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 34.8% NCT03048578 · Phase 4 · registry result, not featured evidence 20.7%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 10% NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence 0% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 20%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 15%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 16.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 19.7%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 31.4% NCT01784965 · Phase 3 · registry result, not featured evidence 8.8% NCT04883346 · Phase 2 · registry result, not featured evidence 55.2% NCT03158805 · Phase 2 · registry result, not featured evidence 11.9% NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 11.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 17.8%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 21.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 19.4%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 10.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 16.7%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 16.7%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 12.5%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | — | 8.5%3.0 mga NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results9.9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9.2%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.5%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 11.1%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT02918279 · Phase 3 —3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 1.1% NCT03048578 · Phase 4 · registry result, not featured evidence —3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence — NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence — NCT03115424 · Phase 3 · registry result, not featured evidence — NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 10.9%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence —Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence —Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 7.6%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 8.5%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence — NCT04883346 · Phase 2 · registry result, not featured evidence — NCT03158805 · Phase 2 · registry result, not featured evidence — NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 5.4%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 5.6%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.7%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 3.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 4.2%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence —420 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —210 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —70 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence |
| Serious AEs | — | 4.2%3.0 mga NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results15.1%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 6.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 8.8%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.6%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.4%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 2.4%3.0 mg NCT02918279 · Phase 3 16.5%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 4.5% NCT03048578 · Phase 4 · registry result, not featured evidence 0%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 0% NCT02911818 · Phase 4 · registry result, not featured evidence 0% NCT01562678 · Phase 4 · registry result, not featured evidence 8.3% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 0%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 5%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 8.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence 4.2%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence 0% NCT04883346 · Phase 2 · registry result, not featured evidence 0% NCT03158805 · Phase 2 · registry result, not featured evidence 1.5% NCT03523273 · Phase 2 · registry result, not featured evidence 0% NCT02647944 · Phase 2 · registry result, not featured evidence 10.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 11.1%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 7.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 6.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 0%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0% NCT03041792 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | — | 3.0 mga nausea 47.6% (placebo 17.1%) constipation 26.9% (placebo 12.4%) diarrhoea 17.9% (placebo 12.4%) NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results3.0 mg nausea 40.8% (placebo 17%) nasopharyngitis 26.5% (placebo 27.8%) diarrhoea 25.5% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg nausea 43.7% (placebo 17%) constipation 21.2% (placebo 11.3%) diarrhoea 21% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg hypoglycaemia 44.3% (placebo 27.8%) nausea 32.7% (placebo 13.7%) diarrhoea 25.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 1.8 mg hypoglycaemia 40% (placebo 27.8%) nausea 31.4% (placebo 13.7%) diarrhoea 17.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.0 mg nausea 26.7% (placebo 6.7%) diarrhoea 16.5% (placebo 7.8%) headache 14.2% (placebo 11.2%) NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 3.0 mg nausea 42.4% (placebo 14.3%) vomiting 34.4% (placebo 4%) nasopharyngitis 27.2% (placebo 30.2%) NCT02918279 · Phase 3 3 mg nausea 41.9% gastrointestinal hypomotility 35.8% diarrhoea 27.7% NCT03036800 · Phase 4 · registry result, not featured evidence · combination nausea 23.6% (placebo 7%) constipation 15.7% (placebo 9.3%) abdominal pain 9% (placebo 2.3%) NCT03048578 · Phase 4 · registry result, not featured evidence 3.0 mg gi related 46.7% (placebo 12.9%) respiratory tract infection 10.9% (placebo 15.1%) injection site reaction 7.6% (placebo 8.6%) NCT03038620 · Phase 4 · registry result, not featured evidence nausea 36% (placebo 4.3%) upper respiratory infection 32% (placebo 8.7%) constipation 30% (placebo 0%) NCT02911818 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 25%) NCT01562678 · Phase 4 · registry result, not featured evidence nausea 16.7% (placebo 11.1%) vomiting 16.7% (placebo 11.1%) hgb < 11.5 g/dl 0% (placebo 0%) NCT03115424 · Phase 3 · registry result, not featured evidence during study 24.7% (placebo 25%) NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 3 mg nausea 25.5% (placebo 11.1%) vomiting 9.1% (placebo 0%) diarrhea 7.3% (placebo 0%) NCT03480022 · Phase 3 · registry result, not featured evidence diarrhoea 50% (placebo 16.7%) abdominal pain 30% (placebo 25%) constipation 15% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence diarrhoea 41.2% (placebo 16.7%) abdominal pain 17.6% (placebo 25%) abdominal pain upper 17.6% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 29.7% (placebo 11.7%) diarrhoea 23.1% (placebo 15.2%) nasopharyngitis 21.5% (placebo 18.3%) NCT02963922 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 47.9% (placebo 17.9%) constipation 30.3% (placebo 18.6%) vomiting 23.2% (placebo 5%) NCT02963935 · Phase 3 · registry result, not featured evidence elective back surgery 2.9% (placebo 0%) family issues 2.9% (placebo 0%) protocol deviation 2.9% (placebo 0%) NCT01784965 · Phase 3 · registry result, not featured evidence dyspepsia 23.5% constipation 11.8% fatigue 11.8% NCT04883346 · Phase 2 · registry result, not featured evidence nausea 65.5% (placebo 45.2%) constipation 41.4% (placebo 9.7%) heartburn 34.5% (placebo 6.5%) NCT03158805 · Phase 2 · registry result, not featured evidence nausea 59.7% (placebo 15.9%) diarrhea 34.3% (placebo 8.7%) abdominal pain/discomfort 28.4% (placebo 5.8%) NCT03523273 · Phase 2 · registry result, not featured evidence nausea 63.2% (placebo 9.5%) headache 26.3% (placebo 19%) abdominal pain/discomfort 21.1% (placebo 9.5%) NCT02647944 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 50.5% nasopharyngitis 40.9% headache 23.7% NCT00422058 · Phase 2 · registry result, not featured evidence 1.8 mg / 3.0 mg nasopharyngitis 37.8% nausea 37.8% gastroenteritis 22.2% NCT00422058 · Phase 2 · registry result, not featured evidence 2.4 mg / 3.0 mg nasopharyngitis 45.2% nausea 41.9% headache 24.7% NCT00422058 · Phase 2 · registry result, not featured evidence placebo / 2.4 mg / 3.0 mg nasopharyngitis 41.8% nausea 29.6% headache 23.5% NCT00422058 · Phase 2 · registry result, not featured evidence 1.2 mg / 3.0 mg nasopharyngitis 38.9% nausea 36.8% influenza 25.3% NCT00422058 · Phase 2 · registry result, not featured evidence 420 mg abdominal pain 0% (placebo 0%) arthralgia 0% (placebo 0%) back pain 0% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 0%) diarrhoea 33.3% (placebo 0%) upper respiratory tract infection 33.3% (placebo 16.7%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 210 mg upper respiratory tract infection 50% (placebo 16.7%) arthralgia 16.7% (placebo 0%) blood creatine phosphokinase increased 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 66.7% (placebo 16.7%) constipation 33.3% (placebo 0%) early satiety 33.3% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 70 mg back pain 16.7% (placebo 0%) constipation 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence decreased appetite 62.5% (placebo 0%) lipase increased 37.5% (placebo 0%) nausea 25% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination nausea 46.9% (placebo 3.6%) diarrhoea 34.4% (placebo 14.3%) headache 34.4% (placebo 10.7%) NCT03041792 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Saxenda)
show 4 more results
show 3 more results
show 24 more results
show 1 more result
show 1 more result
show 1 more result
+ 188 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · Liraglutide (Saxenda)'s landscape